{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:21:46Z","timestamp":1777396906665,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2019,5,7]]},"DOI":"10.3233\/jad-180321","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T15:59:40Z","timestamp":1534867180000},"page":"37-48","source":"Crossref","is-referenced-by-count":26,"title":["Plasma A\u03b242 as a Biomarker of Prodromal Alzheimer\u2019s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog\/E-ADNI Study"],"prefix":"10.1177","volume":"69","author":[{"given":"Diego","family":"Albani","sequence":"first","affiliation":[{"name":"Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy"}]},{"name":"PharmaCog Consortium","sequence":"additional","affiliation":[]},{"given":"Moira","family":"Marizzoni","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroimaging and Alzheimer\u2019s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy"}]},{"given":"Clarissa","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Unit of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy"}]},{"given":"Federica","family":"Fusco","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy"}]},{"given":"Lucia","family":"Boeri","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy"}]},{"given":"Ilaria","family":"Raimondi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy"}]},{"given":"Jorge","family":"Jovicich","sequence":"additional","affiliation":[{"name":"MR Lab Head, Center for Mind\/Brain Sciences, University of Trento, Italy"}]},{"given":"Claudio","family":"Babiloni","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology \u201cV. Erspamer\u201d, Sapienza University of Rome, Rome, Italy"},{"name":"Department of Neuroscience, IRCCS San Raffaele Pisana of Rome and Cassino, Rome and Cassino, Italy"}]},{"given":"Andrea","family":"Soricelli","sequence":"additional","affiliation":[{"name":"IRCCS SDN Istituto di Ricerca Diagnostica e Nucleare, Napoli, Italy"}]},{"given":"Roberta","family":"Lizio","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology \u201cV. Erspamer\u201d, Sapienza University of Rome, Rome, Italy"}]},{"given":"Samantha","family":"Galluzzi","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroimaging and Alzheimer\u2019s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy"}]},{"given":"Libera","family":"Cavaliere","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroimaging and Alzheimer\u2019s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy"}]},{"given":"Mira","family":"Didic","sequence":"additional","affiliation":[{"name":"Aix-Marseille Universit\u00e9, INSERM, INS UMR_S 1106, Marseille, France"},{"name":"APHM, Timone, Service de Neurologie et Neuropsychologie, APHM H\u00f4pital Timone Adultes, Marseille, France"}]},{"given":"Peter","family":"Sch\u00f6nknecht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany, Germany"}]},{"given":"Jos\u00e9 Luis","family":"Molinuevo","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Unit and Other Cognitive Disorders Unit, Hospital Cl\u00ednic de Barcelona, and Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain"}]},{"given":"Flavio","family":"Nobili","sequence":"additional","affiliation":[{"name":"Clinical Neurology, Dept. of Neuroscience (DINOGMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy"}]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[{"name":"Clinica Neurologica, Universit\u00e0 di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy"}]},{"given":"Pierre","family":"Payoux","sequence":"additional","affiliation":[{"name":"INSERM, Imagerie c\u00e9r\u00e9brale et handicaps neurologiques UMR 825, Toulouse, France"}]},{"given":"Luisella","family":"Bocchio","sequence":"additional","affiliation":[{"name":"Genetic Unit, IRCCS Centro Giovanni di Dio, Fatebenefratelli, Brescia, Italy; Faculty of Psychology, University eCampus, Novedrate (Como), Italy"}]},{"given":"Marco","family":"Salvatore","sequence":"additional","affiliation":[{"name":"IRCCS SDN Istituto di Ricerca Diagnostica e Nucleare, Napoli, Italy"}]},{"given":"Paolo Maria","family":"Rossini","sequence":"additional","affiliation":[{"name":"Department of Gerontology, Neurosciences and Orthopedics, Catholic University, Rome, Italy"},{"name":"Policlinic A. Gemelli Foundation"}]},{"given":"Magda","family":"Tsolaki","sequence":"additional","affiliation":[{"name":"3rd Neurologic Clinic, Medical School, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, The Netherlands"}]},{"given":"Jill C.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, United Kingdom"}]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[{"name":"LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany"},{"name":"Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August-University, Goettingen, Germany"},{"name":"iBiMED, Medical Sciences Department, University of Aveiro, Aveiro, Portugal"}]},{"given":"R\u00e9gis","family":"Bordet","sequence":"additional","affiliation":[{"name":"University of Lille, Inserm, CHU Lille, U1171 - Degenerative and vascular cognitive disorders, Lille, France"}]},{"given":"Olivier","family":"Blin","sequence":"additional","affiliation":[{"name":"Aix Marseille University, UMR-CNRS 7289, Service de Pharmacologie Clinique, AP-HM, Marseille, France"}]},{"given":"Gianluigi","family":"Forloni","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[{"name":"Laboratory of Neuroimaging and Alzheimer\u2019s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy"},{"name":"Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-180321_ref1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"issue":"s1","key":"10.3233\/JAD-180321_ref2","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.3233\/JAD-179926","article-title":"From cerebrospinal fluid to blood: The third wave of fluid biomarkers for Alzheimer\u2019s disease","volume":"64","author":"Zetterberg","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-180321_ref3","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3233\/JAD-170531","article-title":"A decade of blood biomarkers for Alzheimer\u2019s disease research: An evolving field, improving study designs, and the challenge of replication","volume":"62","author":"Shi","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-180321_ref4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180321_ref5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neurobiolaging.2017.05.012","article-title":"Multivariate analyses of peripheral blood leukocyte transcripts distinguish Alzheimer\u2019s, Parkinson\u2019s, control, and those at risk for developing Alzheimer\u2019s","volume":"58","author":"Delvaux","year":"2017","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-180321_ref6","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1093\/hmg\/ddx267","article-title":"MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer\u2019s disease","volume":"1","author":"Kumar","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JAD-180321_ref7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.3233\/JAD-180321_ref8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","article-title":"Plasma amyloid levels within the Alzheimer\u2019s process and correlations with central biomarkers","volume":"14","author":"Hanon","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180321_ref9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","article-title":"Plasma amyloid \u03b2 42\/40 ratios as biomarkers for amyloid \u03b2 cerebral deposition in cognitively normal individuals","volume":"8","author":"Fandos","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-180321_ref10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jalz.2016.12.004","article-title":"Plasma concentrations of free amyloid \u03b2 cannot predict the development of Alzheimer\u2019s disease","volume":"13","author":"L\u00f6vheim","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180321_ref11","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-180321_ref12","first-page":"CD008782","article-title":"Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"6","author":"Ritchie","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JAD-180321_ref13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/alzrt162","article-title":"Plasma amyloid beta measurements - a desired but elusive Alzheimer\u2019s disease biomarker","volume":"5","author":"Toledo","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-180321_ref14","doi-asserted-by":"crossref","first-page":"e59676","DOI":"10.1371\/journal.pone.0059676","article-title":"Genetic loci associated with Alzheimer\u2019s disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort","volume":"8","author":"Elias-Sonnenschein","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JAD-180321_ref15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.2011.381","article-title":"Plasma clusterin and the risk of Alzheimer disease","volume":"305,","author":"Schrijvers","year":"2011","journal-title":"JAMA"},{"key":"10.3233\/JAD-180321_ref16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3233\/JAD-150036","article-title":"Clusterin levels in plasma predict cognitive decline and progression to Alzheimer\u2019s disease","volume":"46","author":"Jongbloed","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-180321_ref17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.dadm.2015.12.001","article-title":"Plasma apolipoprotein J as a potential biomarker for Alzheimer\u2019s disease: Australian Imaging, Biomarkers and Lifestyle study of aging","volume":"3","author":"Gupta","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-180321_ref18","doi-asserted-by":"crossref","first-page":"e0190478","DOI":"10.1371\/journal.pone.0190478","article-title":"Associations of plasma clusterin and Alzheimer\u2019s disease-related MRI markers in adults at mid-life: The CARDIA Brain MRI sub-study","volume":"13","author":"Haight","year":"2018","journal-title":"PLoS One"},{"key":"10.3233\/JAD-180321_ref19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/joim.12482","article-title":"Clinical and biomarker profiling of prodromal Alzheimer\u2019s disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: A \u2018European ADNI study\u2019","volume":"279","author":"Galluzzi","year":"2016","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-180321_ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2017.01.013","article-title":"Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI)","volume":"53","author":"Nathan","year":"2017","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-180321_ref21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180321_ref22","doi-asserted-by":"crossref","first-page":"P1319","DOI":"10.1016\/j.jalz.2017.06.2024","article-title":"CSF biomarkers and effect of apolipoprotein E genotype, age and sex on cut-off derivation in mild cognitive impairment","volume":"13","author":"Marizzoni","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180321_ref23","doi-asserted-by":"crossref","DOI":"10.1002\/0471721182","volume-title":"Finite Mixture Models","author":"McLachlan","year":"2000"},{"key":"10.3233\/JAD-180321_ref24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing-when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.3233\/JAD-180321_ref25","doi-asserted-by":"crossref","first-page":"e1002482","DOI":"10.1371\/journal.pmed.1002482","article-title":"Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study","volume":"15","author":"Varma","year":"2018","journal-title":"PLoS Med"},{"key":"10.3233\/JAD-180321_ref26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-017-0324-0","article-title":"Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer\u2019s disease","volume":"9,","author":"Wang","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-180321_ref27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jprot.2017.12.018","article-title":"Gender-related increase of tropomyosin-1 abundance in platelets of Alzheimer\u2019s disease and mild cognitive impairment patients","volume":"178","author":"Reumiller","year":"2018","journal-title":"J Proteomics"},{"key":"10.3233\/JAD-180321_ref28","doi-asserted-by":"crossref","first-page":"14057","DOI":"10.1038\/s41598-017-14020-9","article-title":"A blood-based biomarker panel indicates IL-10 and IL-12\/23p40 are jointly associated as predictors of \u03b2-amyloid load in an AD cohort","volume":"7,","author":"Pedrini","year":"2017","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-180321_ref29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neurobiolaging.2016.12.029","article-title":"Mitochondrial genes are altered in blood early in Alzheimer\u2019s disease","volume":"53","author":"Lunnon","year":"2017","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-180321_ref30","first-page":"0168816","article-title":"Usefulness of DNA methylation levels in COASY and SPINT1 gene promoter regions as biomarkers in diagnosis of Alzheimer\u2019s disease and amnestic mild cognitive impairmente","volume":"11","author":"Kobayashi","year":"2016","journal-title":"PLoS One"},{"key":"10.3233\/JAD-180321_ref31","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jalz.2016.02.009","article-title":"Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: The relation to Alzheimer\u2019s diseaseathology","volume":"12","author":"Yu","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180321_ref32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.dadm.2017.04.003","article-title":"Altered levels of blood proteins in Alzheimer\u2019s disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort","volume":"8","author":"Gupta","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-180321_ref33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jama.1994.03510370037029","article-title":"A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer\u2019s disease. The Tacrine Study Group","volume":"271","author":"Knapp","year":"1994","journal-title":"JAMA"},{"key":"10.3233\/JAD-180321_ref34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.trci.2017.08.010","article-title":"Potential implications of practice effects in Alzheimer\u2019s disease prevention trials","volume":"3","author":"Jacobs","year":"2017","journal-title":"Alzheimers Dement (NY)"},{"key":"10.3233\/JAD-180321_ref35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-140771","article-title":"Amyloid-\u03b2 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer\u2019s disease: Validation of two novel assays","volume":"43","author":"Lewczuk","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-180321_ref36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.neurobiolaging.2007.08.010","article-title":"Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment","volume":"30","author":"Brys","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-180321_ref37","doi-asserted-by":"crossref","unstructured":"Nabers A , Perna L , Lange J , Mons U , Schartner J , G\u00fcldenhaupt J , Saum KU , Janelidze S , Holleczek B , Rujescu D , Hansson O , Gerwert K , Brenner H (2018) Amyloid blood biomarker detects Alzheimer\u2019s disease. EMBO Mol Med 10, e8763.","DOI":"10.15252\/emmm.201708763"},{"key":"10.3233\/JAD-180321_ref38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2007.09.023","article-title":"The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer\u2019s disease","volume":"427","author":"Giedraitis","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-180321_ref39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jalz.2012.01.001","article-title":"Improved protocol for measurement of plasma \u03b2-amyloid in longitudinal evaluation of Alzheimer\u2019s Disease Neuroimaging Initiative study patients","volume":"8","author":"Figurski","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-180321_ref40","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3233\/JAD-170784","article-title":"Plasma amyloid-\u03b2 (A\u03b242) Correlates with cerebrospinal fluid A\u03b242 in Alzheimer\u2019s disease","volume":"62","author":"Teunissen","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-180321_ref41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archgenpsychiatry.2010.78","article-title":"Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease","volume":"67","author":"Thambisetty","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.3233\/JAD-180321_ref42","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2174\/1567205014666170531080948","article-title":"\u03b2-amyloid upregulates intracellular clusterin but not secretory clusterin in primary cultured neurons and APP mice","volume":"14","author":"Wang","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-180321_ref43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jamaneurol.2013.4560","article-title":"The role of clusterin in amyloid-\u03b2-associated neurodegeneration","volume":"71","author":"Desikan","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-180321_ref44","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-180321_ref45","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/archneurol.2010.147","article-title":"Replication of CLU, CR1, and PICALM associations with Alzheimer disease","volume":"67","author":"Carrasquillo","year":"2010","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-180321_ref46","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-180321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:29Z","timestamp":1777370969000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-180321"}},"subtitle":[],"editor":[{"given":"George","family":"Perry","sequence":"additional","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":46,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-180321","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]}}}